(NASDAQ: TRDA) Entrada Therapeutics's forecast annual revenue growth rate of -13.66% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.33%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.78%.
Entrada Therapeutics's revenue in 2025 is $79,476,000.On average, 3 Wall Street analysts forecast TRDA's revenue for 2025 to be $1,239,248,034, with the lowest TRDA revenue forecast at $894,251,727, and the highest TRDA revenue forecast at $1,929,240,647. On average, 2 Wall Street analysts forecast TRDA's revenue for 2026 to be $1,358,304,091, with the lowest TRDA revenue forecast at $570,556,185, and the highest TRDA revenue forecast at $2,146,051,997.
In 2027, TRDA is forecast to generate $2,146,051,997 in revenue, with the lowest revenue forecast at $2,146,051,997 and the highest revenue forecast at $2,146,051,997.